The pulmonary physician in critical care • 9: Non-ventilatory strategies in ARDS

Thorax

Volumn 57, Issue 9, 2002, Pages 823-829

  Cranshaw, J ^a   Griffiths, M J D ^a   Evans, T W ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACETYLCYSTEINE; ANTIOXIDANT; ASCORBIC ACID; CORTICOSTEROID; FLAVONOID; GLUTATHIONE; INFUSION FLUID; LIPOXYGENASE INHIBITOR; LUNG SURFACTANT; METHYLPREDNISOLONE; NITRIC OXIDE; PHOSPHATIDIC ACID; PROSTAGLANDIN E1; THROMBOXANE SYNTHASE INHIBITOR; TOCOPHEROL; VASODILATOR AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CRITICAL ILLNESS; DRUG MEGADOSE; HUMAN; INTENSIVE CARE; NONHUMAN; NUTRITION; PHYSICIAN; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; STEROID THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ANTIOXIDANTS; ARACHIDONATE 5-LIPOXYGENASE; CRITICAL CARE; EPOPROSTENOL; FLUID THERAPY; HUMANS; NITRIC OXIDE; PHOSPHATIDIC ACIDS; PROSTAGLANDINS E, SYNTHETIC; PULMONARY SURFACTANTS; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY DISTRESS SYNDROME, ADULT; THROMBOXANE-A SYNTHASE; VASODILATOR AGENTS;

EID: 0036731801     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thorax.57.9.823     Document Type: Review

References (75)

1. Definitions, mechanisms, relevant outcomes, and clinical trial coordination
2. Reduced mortality in association with the acute respiratory distress syndrome (ARDS)
3. Extravascular lung water and acute respiratory distress syndrome: Oxygenation and outcome
4. Improved survival in ARDS patients associated with a reduction in pulmonary capillary wedge pressure
5. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization
6. Fluid balance during pulmonary edema. Is fluid gain a marker or a cause of poor outcome?
7. Inhaled nitric oxide and acute lung injury
8. Effects of inhaled nitric oxide on right ventricular function in severe acute respiratory distress syndrome
9. Effects of various timings and concentrations of inhaled nitric oxide in lung ischemia-reperfusion
10. Reactive oxygen species in acute lung injury
11. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomized phase II trial
12. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome
13. Inhaled nitric oxide versus conventional therapy: Effect on oxygenation in ARDS
14. Inhaled nitric oxide in acute respiratory distress syndrome: A pilot randomized controlled study
15. Inhaled nitric oxide for the adult respiratory distress syndrome
16. UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs
17. Effect of almitrine on ventilatian-perfusion distribution in adult respiratory distress syndrome
18. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome
19. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome
20. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome
21. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure
22. Methylprednisolone. Pharmacologic doses in shock lung syndrome
23. Pulmonary response of massive steroids in seriously injured patients
24. Early steroid therapy for respiratory failure
25. High-dose corticosteroids in patients with the adult respiratory distress syndrome
26. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock
27. Global analysis of gene expression in pulmonary fibrosis reveals distinct programs regulating lung inflammation and fibrosis
28. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: A randomized controlled trial
29. Corticosteroid therapy in acute respiratory distress syndrome: Better late than never?
30. Comparative effects of some serum components and proteolytic products of fibrinogen on surface tension-lowering abilities of beractant and a synthetic peptide containing surfactant KL4
31. Inhibitory effects of oxyradicals on surfactant function: Utilizing in vitro Fenton reaction
32. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome
33. Bovine surfactant therapy for patients with acute respiratory distress syndrome
34. Bronchopulmonary segmental lavage with Surfaxin (KL(4)-surfactant) for acute respiratory distress syndrome
35. 2 and reduces the period of ventilation in artificially ventilated patients
36. Route and type of nutrition influence mucosal immunity to bacterial pneumonia
37. Anticatabolic and anabolic strategies in critical illness: A review of current treatment modalities
38. Dietary lipids: Ancestral ligands and regulators of cell signaling pathways
39. Effect of enteral feeding with eicosapentaenoic acid, gamma-linolenic acid, and antioxidants in patients with acute respiratory distress syndrome
40. Immunonutrition in the critically ill: A systematic review of clinical outcome
41. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial
42. Prostaglandin E1 and survival in patients with the adult respiratory distress syndrome. A prospective trial
43. Randomized double-blind, multicenter study of prostaglandin E1 in patients with the adult respiratory distress syndrome
44. Liposomal prostaglandin E1 in acute respiratory distress syndrome: A placebo-controlled, randomized, double-blind, multicenter clinical trial
45. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: A controlled, randomized, double-blind, multicenter clinical trial
46. Liposome-entrapped PGE1 posttreatment decreases IL-1 alpha-induced neutrophil accumulation and lung leak in rats
47. Prostaglandins, cyclo-oxygenase inhibitors, and thromboxane synthetase inhibitors in the pathogenesis of multiple systems organ failure
48. Role of humoral mediators in adult respiratory distress syndrome
49. Biological markers of acute lung injury: Prognostic and pathogenetic significance
50. Ketoconazole inhibits the biosynthesis of leukotrienes in vitro and in vivo
51. Ketoconazole prevents acute respiratory failure in critically ill surgical patients
52. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome
53. Development, implementation, and evaluation of a ketoconazole practice guideline for ARDS prophylaxis
54. Ketoconazole for early treatment of acute lung injury and acute respiratory distress syndrome: A randomized controlled trial
55. Oxidant-antioxidant balance in acute respiratory distress syndrome
56. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome
57. N-acetylcysteine in experimental and clinical acute lung injury
58. Protective effects of N-acetylcysteine and rutin on the lipid peroxidation of the lung epithelium during the adult respiratory distress syndrome
59. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: A prospective, randomized, placebo-controlled study
60. Treatment with N-acetylcysteine during acute respiratory distress syndrome: A randomized, double-blind, placebo-controlled clinical study
61. A trial of antioxidants N-acetylcysteine and procysteine in ARDS
62. Lysofylline versus placebo for ALI and ARDS
63. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock
64. The effects of ibuprofen on the physiology and survival of patients with sepsis
65. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial
66. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial
67. Intersept: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis
68. Efficacy and safety of recombinant human activated protein C for severe sepsis
69. Inhalation of nitric oxide in acute lung injury: Results of a European multicentre study
70. Established ARDS treated with a sustained course of adrenocortical steroids
71. Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS
72. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome?
73. Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome
74. Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids
75. Ineffectiveness of high-dose methylprednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock